Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: The present invention is within the field of transplantation surgery. More closely, the present invention relates to use of a clotting preventing agent in the production of a drug for administration in association with transplantation of insulin producing cells in the form of isolated islets to patients with insulin dependent diabetes mellitus, IDDM. The invention is expected to significantly improve the clinical outcome of transplantation of islets of Langerhans.

Abstract: A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.

Abstract: Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: The present invention relates to a particle board comprising a lower and an upper surface layer (9, 11) having a finer fraction of particles (4), and between these surface layers (9, 11) an intermediate layer (13) having a coarser fraction of particles (5). The intermediate layer (13) has a varying density.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: A chip board including an intermediary layer (1) and a layer (2) of large chips positioned on both sides of said intermediary layer. An outer layer (3) is provided on the 5 outer surface of each layer of large chips. In addition to the chips, the layers include an adhesive. The intermediary layer (1) includes a mixture of wood chips having chip fractions of a chip size of 0.1 to 20 mm, and the chips of this layer are randomly oriented. The individual chip in the layer (2) of large chips presents the following characteristics: a length of approx. 50 to approx. 130 mm, a width of approx. 4 to approx. 40 mm and a thickness of approx. 0.2 to approx. 2.0 mm. The chips within each layer (2) of large chips are all oriented in one and the same direction. As a result, a chip board is obtained which demonstrates a significantly higher E-module and stiffness in flexure than hitherto known despite a reduced consumption of material.

Abstract: The invention relates to an adapter (5) for a fixation pin (2) of the type which is adapted for fixating a supporting structure to a bony structure of a human or animal body part, and which is provided with a shank portion (4). The adapter (5) comprises a sharp-pointed tip (7), for penetration into the bony structure of the body part, and an engagement formation (8) for removable connection to an inner end of said shank portion (4). The invention also relates to a fixation pin and a method for fixating a supporting structure to a human or animal body part.

Abstract: The method is for treating a liquid or slurry with an ultrasonic energy. A movable endless member is provided that is permeable to a liquid. A transverse foil is disposed below the member and extends across the member and a transducer is in operative engagement with the foil. The member is moved about rollers. The transducer generates pressure pulses into the foil to form implosion bubbles in the liquid disposed above the member. The implosion bubbles have a first diameter (d1). A gap is formed between the member and the foil. The gap represents a distance (d2) that is less than the diameter (d1) of the bubbles to prevent any bubbles of critical size to be captured in the gap.

Abstract: A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.

Abstract: A chip board including an intermediary layer (1) and a layer (2) of large chips positioned on both sides of said intermediary layer. An outer layer (3) is provided on the 5 outer surface of each layer of large chips. In addition to the chips, the layers include an adhesive. The intermediary layer (1) includes a mixture of wood chips having chip fractions of a chip size of 0.1 to 20 mm, and the chips of this layer are randomly oriented. The individual chip in the layer (2) of large chips presents the following characteristics: a length of approx. 50 to approx. 130 mm, a width of approx. 4 to approx. 40 mm and a thickness of approx. 0.2 to approx. 2.0 mm. The chips within each layer (2) of large chips are all oriented in one and the same direction. As a result, a chip board is obtained which demonstrates a significantly higher E-module and stiffness in flexure than hitherto known despite a reduced consumption of material.

Abstract: According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.

Abstract: The present invention relates to use of an inhibitor or antagonist against tissue factor, TF, in the production of a drug for treatment or prevention of diabetes or diabetes related diseases. The inhibitor or antagonist is mainly intended for treatment of diabetic patients suffering from type I or type II diabetes, respectively, as well as the metabolic syndrome preceding type II diabetes. The inhibitor or antagonist is an agent which completely or partially inhibits TF productions, such as an anti-TF antibody or an antisense construct acting on the TF gene.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: The present invention relates to a device for fixation to a patient during neurological diagnosis, therapy or surgery, in particular during MRI diagnosis. The device comprises at least one fixation pin being made of a non-magnetic, electrically conductive material for fixation to a patient, and at least one pin support member for supporting said fixation pin. An insulation means is arranged so as to restrict the electrical coupling between said pin support member and fixation pin. Said insulation means is sleeve shaped and arranged to at least partly surround said fixation pin. The invention also relates to an insulation means, a pin support member and to a method for assembling a fixation device.

Abstract: Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.

Abstract: Acccording to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.